Serina Financial Statements From 2010 to 2024

SER Stock   4.79  0.64  15.42%   
Serina Therapeutics financial statements provide useful quarterly and yearly information to potential Serina Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Serina Therapeutics financial statements helps investors assess Serina Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Serina Therapeutics' valuation are summarized below:
Quarterly Earnings Growth
3.568
Profit Margin
(2.21)
Market Capitalization
57.2 M
Revenue
3.2 M
Earnings Share
0.14
There are over one hundred nineteen available fundamental trend indicators for Serina Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Serina Therapeutics' current fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 12/18/2024, Market Cap is likely to drop to about 23.2 M. In addition to that, Enterprise Value is likely to drop to about 24.6 M

Serina Therapeutics Total Revenue

134,900

Check Serina Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Serina Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 124.5 K, Total Revenue of 134.9 K or Other Operating Expenses of 6.8 M, as well as many indicators such as Price To Sales Ratio of 148, Dividend Yield of 0.0 or PTB Ratio of 2.58. Serina financial statements analysis is a perfect complement when working with Serina Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Serina Therapeutics Correlation against competitors.
To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.

Serina Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12.6 M12 MM
Very volatile
Short and Long Term Debt Total3.3 M4.4 M2.4 M
Slightly volatile
Other Current Liabilities791.5 K829 K1.7 M
Slightly volatile
Total Current Liabilities3.4 M5.9 M3.2 M
Very volatile
Property Plant And Equipment Net519.9 K278.5 K893.1 K
Slightly volatile
Current Deferred Revenue0.951.0227.5 K
Slightly volatile
Accounts Payable1.5 M1.4 M543.1 K
Slightly volatile
Cash651.4 K345 K1.7 M
Slightly volatile
Non Current Assets Total11.8 M11.2 MM
Slightly volatile
Cash And Short Term Investments327.8 K345 K1.8 M
Slightly volatile
Net Receivables54.1 K57 K271.5 K
Slightly volatile
Common Stock Shares Outstanding1.2 M1.1 M1.1 M
Slightly volatile
Liabilities And Stockholders Equity12.6 M12 MM
Very volatile
Non Current Liabilities Total658.4 K693 K6.4 M
Slightly volatile
Other Current Assets504.8 K352 KM
Slightly volatile
Other Stockholder Equity102.5 M136.5 M90.9 M
Slightly volatile
Total Liabilities6.3 M6.6 M9.7 M
Slightly volatile
Total Current Assets1.4 M754 K3.1 M
Slightly volatile
Accumulated Other Comprehensive Income116.6 K164.4 K93.3 K
Slightly volatile
Short Term Debt3.9 M3.7 M969.6 K
Slightly volatile
Common Stock14.2 K25.5 K8.5 K
Slightly volatile
Capital Lease Obligations235.9 K172.5 K358.5 K
Slightly volatile
Property Plant And Equipment Gross608.8 K609.3 K802.3 K
Slightly volatile
Capital Stock24 K25.5 K21.9 K
Slightly volatile
Net Working Capital94.8 K99.8 K787.4 K
Slightly volatile
Long Term Debt1.3 M1.5 M1.6 M
Slightly volatile
Intangible Assets485.6 K546.3 K594.9 K
Slightly volatile

Serina Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization124.5 K131 K752.2 K
Slightly volatile
Total Revenue134.9 K142 K1.4 M
Slightly volatile
Other Operating Expenses6.8 M10.1 M11.8 M
Slightly volatile
Research Development572.9 K603 K4.2 M
Slightly volatile
Cost Of Revenue162.4 K171 K793 K
Slightly volatile
Total Operating Expenses6.4 M9.9 M11.1 M
Slightly volatile
Interest Expense5.1 M4.9 M967.2 K
Slightly volatile
Interest Income1.5 K1.6 KK
Slightly volatile
Selling General AdministrativeM1.2 M1.3 M
Slightly volatile
Reconciled Depreciation52.1 K70.5 K38.9 K
Slightly volatile

Serina Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow612.8 K645 K4.8 M
Slightly volatile
Depreciation124.5 K131 K741 K
Slightly volatile
Total Cash From Financing Activities18.4 M17.5 M7.1 M
Slightly volatile
End Period Cash Flow651.4 K345 K1.7 M
Slightly volatile
Investments992.3 K1.1 M865.4 K
Slightly volatile
Stock Based Compensation6.1 K6.4 K67.7 K
Slightly volatile
Issuance Of Capital Stock3.8 KK72.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio148104132
Pretty Stable
Days Sales Outstanding125132215
Pretty Stable
Average Payables817.1 K778.2 K231.5 K
Slightly volatile
Stock Based Compensation To Revenue0.02290.01640.0254
Slightly volatile
Capex To Depreciation0.140.1580.5405
Pretty Stable
EV To Sales161133142
Pretty Stable
Payables Turnover0.110.1213.0338
Slightly volatile
Sales General And Administrative To Revenue1.22.320.7481
Slightly volatile
Research And Ddevelopement To Revenue4.034.24658.1841
Pretty Stable
Capex To Revenue0.02120.02230.1529
Pretty Stable
Cash Per Share0.30.31971.3878
Pretty Stable
Days Payables Outstanding3.2 KK540
Slightly volatile
Income Quality0.720.52690.7478
Slightly volatile
Intangibles To Total Assets0.04060.04570.0497
Slightly volatile
Current Ratio0.120.12751.0621
Pretty Stable
Receivables Turnover2.132.24188
Pretty Stable
Graham Number44.8339.554860.1988
Slightly volatile
Capex Per Share0.00980.01030.1879
Very volatile
Average Receivables606638131 K
Slightly volatile
Revenue Per Share0.130.13161.2973
Slightly volatile
Interest Debt Per Share9.028.58671.9502
Slightly volatile
Debt To Assets0.350.36480.5811
Slightly volatile
Days Of Payables Outstanding3.2 KK540
Slightly volatile
Ebt Per Ebit0.831.4871.1541
Slightly volatile
Quick Ratio0.120.12751.6234
Slightly volatile
Net Income Per E B T0.780.90.9285
Pretty Stable
Cash Ratio0.05540.05830.762
Pretty Stable
Days Of Sales Outstanding125132215
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.161.00471.0463
Slightly volatile
Fixed Asset Turnover1.771.866.9868
Slightly volatile
Debt Ratio0.350.36480.5811
Slightly volatile
Price Sales Ratio148104132
Pretty Stable
Asset Turnover0.01130.01190.4263
Pretty Stable

Serina Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap23.2 M24.5 M74.8 M
Slightly volatile
Enterprise Value24.6 M25.9 M74.8 M
Slightly volatile

Serina Fundamental Market Drivers

Cash And Short Term Investments345 K

About Serina Therapeutics Financial Statements

Serina Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Serina Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Serina Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Serina Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue 1.00  0.95 
Total Revenue142 K134.9 K
Cost Of Revenue171 K162.4 K
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 2.32  1.20 
Research And Ddevelopement To Revenue 4.25  4.03 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.13  0.13 
Ebit Per Revenue(70.14)(73.65)

Pair Trading with Serina Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Serina Stock

  0.79VALN Valneva SE ADRPairCorr
  0.62ERNA Eterna TherapeuticsPairCorr

Moving against Serina Stock

  0.73GILD Gilead SciencesPairCorr
  0.71BMY Bristol Myers SquibbPairCorr
  0.62DYAI Dyadic InternationalPairCorr
  0.53ESPR Esperion Therapeutics Buyout TrendPairCorr
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Serina Stock Analysis

When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.